Literature DB >> 28573370

Association of tumor necrosis factor-α (G-308A) genetic variant with matrix metalloproteinase-9 activity and joint destruction in early rheumatoid arthritis.

Sonja Stojanovic1, Tatjana Jevtovic Stoimenov2, Jovan Nedovic3, Valentina Zivkovic4, Milena Despotovic2, Dusica Pavlovic2.   

Abstract

Matrix metalloproteinases (MMPs) are the key enzymes responsible for the joint destruction. Their activity is regulated by the level of proinflammatory cytokines. The aim of this study was to examine the impact of TNF-α G-308A polymorphism on MMP-9 levels in blood plasma (BP) and synovial fluid (SF) of patients with rheumatoid arthritis (RA) and their role in progression of joint destruction. One hundred thirty-four subjects were enrolled in this study. TNF-α G-308A polymorphism was determined using PCR-RFLP method. ELISA assay was used for the detection of MMP-9 activity in BP and SF. Joint damage was estimated by hands and feet radiography. Larsen score and annual changes in LS were used for quantitative evaluation of joint destruction and radiographic progression of disease. MMP-9 activity in BP and SF was significantly higher in RA compared to controls, as well as in SF of patients with erosive compared to nonerosive RA. Faster radiographic progression and increased MMP-9 activity in BP and SF were detected in the group A (GA or AA genotype carriers) compared to the group G (GG genotype carriers). However, statistical significance was revealed only for MMP-9 activity in SF (p < 0.05). MMP-9 activity in BP and SF is significantly higher in RA patients compared to patients with osteoarthritis. The presence of TNF-α-308A allele is associated with increased MMP-9 activity in SF of patients with early RA and may be a predictor of rapid radiographic progression of disease.

Entities:  

Keywords:  Matrix metalloproteinase 9; Rheumatoid arthritis; Single nucleotide polymorphism; Tumor necrosis factor–α

Mesh:

Substances:

Year:  2017        PMID: 28573370     DOI: 10.1007/s10067-017-3699-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  31 in total

1.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  MAP kinase activation is required for the MMP-9 induction by TNF-stimulation.

Authors:  Kyung Chan Kim; Chu Hee Lee
Journal:  Arch Pharm Res       Date:  2005-11       Impact factor: 4.946

Review 3.  Rheumatoid arthritis.

Authors:  David L Scott; Frederick Wolfe; Tom W J Huizinga
Journal:  Lancet       Date:  2010-09-25       Impact factor: 79.321

4.  TNF-alpha G-308A polymorphism is associated with rheumatic fever and correlates with increased TNF-alpha production.

Authors:  Nilgun Sallakci; Gayaz Akcurin; Sadi Köksoy; Firat Kardelen; Aysen Uguz; Mesut Coskun; Halil Ertug; Olcay Yegin
Journal:  J Autoimmun       Date:  2005-07-19       Impact factor: 7.094

5.  Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.

Authors:  Shintaro Hirata; Wanying Li; Satoshi Kubo; Shunsuke Fukuyo; Yasushi Mizuno; Kentaro Hanami; Norifumi Sawamukai; Kunihiro Yamaoka; Kazuyoshi Saito; Nadine A Defranoux; Yoshiya Tanaka
Journal:  Mod Rheumatol       Date:  2016-03-30       Impact factor: 3.023

6.  Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis.

Authors:  H Yamanaka; Y Matsuda; M Tanaka; W Sendo; H Nakajima; A Taniguchi; N Kamatani
Journal:  Arthritis Rheum       Date:  2000-04

Review 7.  Involvement of apoptotic cell death in autoimmune diseases.

Authors:  Atsushi Kawakami; Katsumi Eguchi
Journal:  Med Electron Microsc       Date:  2002-03

8.  Stimulation of the secretion of latent cysteine proteinase activity by tumor necrosis factor alpha and interleukin-1.

Authors:  G Huet; R M Flipo; C Colin; A Janin; B Hemon; M Collyn-d'Hooghe; R Lafyatis; B Duquesnoy; P Degand
Journal:  Arthritis Rheum       Date:  1993-06

9.  Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha.

Authors:  Paola Cordiali-Fei; Elisabetta Trento; Giovanna D'Agosto; Valentina Bordignon; Anna Mussi; Marco Ardigò; Antonio Mastroianni; Antonella Vento; Francesco Solivetti; Enzo Berardesca; Fabrizio Ensoli
Journal:  J Autoimmune Dis       Date:  2006-10-05

10.  Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.

Authors:  Karen Hambardzumyan; Rebecca Bolce; Saedis Saevarsdottir; Scott E Cruickshank; Eric H Sasso; David Chernoff; Kristina Forslind; Ingemar F Petersson; Pierre Geborek; Ronald F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2014-05-08       Impact factor: 19.103

View more
  3 in total

Review 1.  Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines.

Authors:  Irene Maeve Rea; David S Gibson; Victoria McGilligan; Susan E McNerlan; H Denis Alexander; Owen A Ross
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

2.  Assessing the risk of rapid radiographic progression in Hungarian rheumatoid arthritis patients.

Authors:  Edit Végh; János Gaál; Pál Géher; Edina Gömöri; Attila Kovács; László Kovács; Katalin Nagy; Edit Feketéné Posta; László Tamási; Edit Tóth; Eszter Varga; Andrea Domján; Zoltán Szekanecz; Gabriella Szűcs
Journal:  BMC Musculoskelet Disord       Date:  2021-04-02       Impact factor: 2.362

3.  Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.

Authors:  Désirée van der Heijde; Patrick Durez; Georg Schett; Esperanza Naredo; Mikkel Østergaard; Gabriella Meszaros; Francesco De Leonardis; Inmaculada de la Torre; Pedro López-Romero; Douglas Schlichting; Eric Nantz; Roy Fleischmann
Journal:  Clin Rheumatol       Date:  2018-08-04       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.